Cancer Management Guidelines

Indolent & Transformed Lymphoma
Outcomes

Updated: May 2011

Click on the thumbnails below to view full-size images.

Indolent Lymphoma Allo SCT

Lightbox JS v2.0 | Test Page

Indolent Lymphoma Auto SCT

Lightbox JS v2.0 | Test Page

Transformed Lymphoma General

Lightbox JS v2.0 | Test Page

Transformed Lymphoma Auto SCT

Lightbox JS v2.0 | Test Page

Transformed Lymphoma - Impact of Pre-SCT Rituxan Therapy

Lightbox JS v2.0 | Test Page

Transformed Lymphoma Allo SCT

Lightbox JS v2.0 | Test Page

The information contained in these guidelines is a statement of consensus of Leukemia/BMT Program of BC professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these guidelines and documents is at your own risk and is subject to the Leukemia/BMT Program of BC’s terms of use available at Terms of Use.

Privacy Statement
|
Terms of Use
|
hemwebcontact@bccancer.bc.ca
| visitor ip address: 38.107.179.244
© 2011 Leukemia/BMT Program of BC